Sotera Health Co (SHC) Sotera Health Company, headquartered in Broadview Heights, Ohio, delivers essential sterilization, laboratory testing, and advisory services to a global clientele spanning North America, Europe, and various international regions. The firm's sterilization capabilities encompass gamma and electron beam irradiation, alongside ethylene oxide (EO) processing. Through its Nelson Labs division, Sotera Health conducts comprehensive microbiological and analytical chemistry analyses. Additionally, it offers specialized consulting to the medical device and biopharmaceutical industries. Sotera Health serves a diverse array of sectors, including medical device manufacturers, pharmaceutical companies, producers of food and agricultural products, and various commercial, advanced, and specialty application industries. Incorporated in 2017, the company was previously known as Sotera Health Topco, Inc., adopting its current name in October 2020.
Sector: Services-Misc Health & Allied Services, NEC
Industry: Medical - Diagnostics & Research
Sotera Health Company NASDAQ:SHC Healthcare · Medical - Diagnostics & Research
AH Close $18.10 +0.00% vs close
AH Close $18.10 +0.00% vs close
All Press Release SEC Filings News
Press Release
Sotera Health Announces Third-Quarter 2026 Earnings Release Date
Sotera Health will release third-quarter 2026 financial results before the market opens on Tuesday, November 3, 2026.
Management will host a conference call at 9:00 a.m. Eastern Time the same day, with a live webcast available via the company's Investor Relations site and a replay later that day.
The notice contains no financial figures or business updates; it also points investors to website resources covering recent developments, including Ethylene Oxide litigation-related matters.
• 4d ago AI analysis › News
Sotera Health Company (SHC) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
seekingalpha.com • 1mo ago News
Contrasting Sotera Health (NASDAQ:SHC) & WuXi AppTec (OTCMKTS:WUXIF)
defenseworld.net • 2mo ago SEC Filing
SHC: 8-K · leadership change
Sotera Health Company disclosed in an 8-K (Item 5.02) that James C. Neary resigned from its Board of Directors as a Class I director, effective August 13, 2026.
The company stated that Mr. Neary's resignation was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.
In connection with the departure, the Board fixed its size at eleven directors as of the effective date, and no replacement director was named in the filing.
SEC 8-K • 2mo ago AI analysis › News
Sotera Health Q2 Earnings Call Highlights
marketbeat.com • 2mo ago SEC Filing ⚠ 7
SHC: 10-Q · periodic report
Sotera Health reported Q2 2026 net revenues of $321.4 million, up 9.2% year over year, with net income of $53.6 million ($0.19 diluted EPS) versus $8.0 million ($0.03) a year ago. First-half net income reached $80.2 million, swinging from a $5.3 million loss in the prior-year period that had been burdened by $64.9 million of Illinois EO litigation settlement charges.
The company repriced its $1,415.9 million term loan through Amendment No. 7 to the credit agreement on May 20, 2026, cutting the spread by 0.25% to Adjusted Term SOFR plus 2.25%. The weighted average interest rate fell to 6.49% from 7.49%, and net interest expense declined 15.4% to $34.4 million for the quarter.
The filing formalizes a CEO transition: Alton E. Shader's offer letter sets a May 26, 2026 start date with a $1.0 million salary, a $6.0 million sign-on RSU award, and a $6.5 million annual long-term incentive target, while Michael B. Petras, Jr. assumes the Executive Chairman role.
All three segments grew in the quarter — Sterigenics +8.6%, Nordion +15.8%, and Nelson Labs +6.3% — but the company still faces ongoing ethylene oxide tort litigation in California, Georgia, Illinois and New Mexico and carries roughly $2.17 billion of gross debt against $356.7 million of cash.
SEC 10-Q • 2mo ago AI analysis › News
Sotera Health Company (SHC) Q2 2026 Earnings Call Transcript
seekingalpha.com • 2mo ago News
Sotera Health (SHC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com • 2mo ago News
Sotera Health Company (SHC) Beats Q2 Earnings and Revenue Estimates
zacks.com • 2mo ago Press Release ● Major
Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
Sotera Health reported Q2 2026 revenue of $321.4 million, up 9.2% year-over-year, with Adjusted EPS rising 30% to $0.26.
The company raised its full-year 2026 outlook, projecting constant currency revenue growth of 5.25% to 6.75% and Adjusted EBITDA growth of 5.75% to 7.25%.
Balance sheet strength improved with a Net Leverage Ratio of 3.0x, achieving the long-term target, alongside available liquidity of approximately $950 million.
• 2mo ago AI analysis › Press Release
Sotera Health Announces Second-Quarter 2026 Earnings Release Date
Sotera Health plans to announce its second-quarter 2026 financial results before the market opens on Thursday, August 6, 2026.
Management will host a conference call at 9:00 a.m. Eastern Time to discuss the company's operating and financial performance.
Investors are directed to the company's website for updates on recent developments, including information related to Ethylene Oxide.
• 3mo ago AI analysis › SEC Filing
SHC: 8-K · proxy statement
Sotera Health Company held its 2026 annual meeting of stockholders on May 21, 2026, where shareholders elected all four Class III director nominees for three-year terms ending in 2029.
Shareholders approved the advisory compensation of named executive officers with 257.7 million votes in favor versus 6.6 million against, indicating strong support for current pay practices.
The appointment of Ernst & Young LLP as independent auditor for fiscal year 2026 was ratified with 267.3 million votes in favor, reflecting routine governance continuity.
SEC 8-K • 5mo ago SEC Filing
SHC: 8-K · debt financing
Sotera Health Company entered into Amendment No. 7 to its First Lien Credit Agreement on May 20, 2026, refinancing its existing term loans with new repriced term loans totaling $1.416 billion.
The amendment reduces the interest rate spread by 0.25%, setting the new margin at Adjusted Term SOFR plus 2.25% with a 0.00% floor. The repriced term loans amortize at 1.00% per annum and mature on May 30, 2031.
This transaction represents a routine debt refinancing aimed at optimizing the company's capital structure and reducing interest costs, without introducing significant new leverage or dilution.
SEC 8-K • 5mo ago AI analysis › Press Release ⚠ 1
Sotera Health Announces Secondary Offering of Common Stock
Sotera Health announced a secondary offering of 31,838,253 shares of its common stock, all of which are being sold by affiliates of Warburg Pincus and GTCR.
The company will not receive any proceeds from the offering but will pay the expenses as per its Amended and Restated Registration Rights Agreement.
Goldman Sachs & Co. LLC is acting as the underwriter for the offering.
• 5mo ago AI analysis › Press Release
Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook
Sotera Health reported Q1 2026 net revenue of $280 million, up 10% year-over-year, swinging to a net income of $27 million compared to a $13 million loss in the prior year.
The company reaffirmed its full-year 2026 outlook, projecting 5.0% to 6.5% constant currency revenue growth and 5.5% to 7.0% Adjusted EBITDA growth.
Segment performance was mixed, with Sterigenics and Nordion delivering strong constant currency growth, while Nelson Labs saw a slight decline in revenue.
• 5mo ago AI analysis › Press Release
Sotera Health Announces Leadership Transition
Sotera Health announced a planned leadership transition appointing Alton Shader as the new CEO effective May 26, 2026, succeeding Michael B. Petras, Jr.
Mr. Petras will transition to the role of Executive Chairman and remain a full-time employee, assisting with commercial strategy, investor relations, and litigation matters.
Mr. Shader joins from Viant Medical, bringing over 20 years of experience in the medical device industry, including roles at Hill-Rom and Baxter International.
• 5mo ago AI analysis › 
